As reported, PTEN deletion influences the disease progression of both CML and B-ALL by regulating its downstream target Akt1 [21], through which the BCR-ABL fusion gene regulates ABCG2 expression [28]. This evidence concerns the gene ABCG2 and chronic myelogenous leukemia, BCR-ABL1 positive.